Αποτελέσματα Αναζήτησης
20 Μαΐ 2024 · In 2020, ASCO published a guideline on the selection of optimal adjuvant chemotherapy and targeted therapy for breast cancer. 1 This is a rapid recommendation update of that guideline that addresses, in turn, the adjuvant use of the cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors abemaciclib and ribociclib in patients with stage II and III ...
17 Μαρ 2007 · In our institutions, we discuss with our patients the option to keep their port systems for as long as 2 years after adjuvant breast cancer therapy owing to the increased risk of relapse within this period, in particular in high-risk patients.
25 Νοε 2019 · The success rate of ultrasound-guided TIVAPs via the right innominate vein is high with low complications, thus safe and feasible. This technique can provide a new option for chemotherapy of breast cancer patients.
The National Comprehensive Cancer Network (NCCN) guidelines for the treatment of breast cancer describe numerous recommended adjuvant chemotherapy regimens, including sequential anthracycline-cyclophosphamide and taxane (AC-T); concurrent anthracycline-cyclophosphamide and taxane (ACT); anthracycline-cyclophosphamide without taxane (AC ...
20 Σεπ 2024 · This clinical insights article is derived from recommendations in Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer—Cyclin-Dependent Kinase 4 and 6 Inhibitors: ASCO Guideline Rapid Recommendation Update.
28 Ιαν 2021 · The purpose of this guideline is to develop recommendations concerning the optimal use of systemic neoadjuvant therapy, including chemotherapy, endocrine therapy, and targeted therapy for patients with invasive breast cancer.
This study confirms that for women with early-stage breast cancer, at sufficient risk of recurrence and fit enough to be offered chemotherapy, combination anthracycline and taxane chemotherapy provides larger benefit than either drug alone.
